Nothing Special   »   [go: up one dir, main page]

DK2799067T3 - Behandling af hjerneinflammation ved anvendelse af L-Ornithin-phenylacetat - Google Patents

Behandling af hjerneinflammation ved anvendelse af L-Ornithin-phenylacetat Download PDF

Info

Publication number
DK2799067T3
DK2799067T3 DK14175859.9T DK14175859T DK2799067T3 DK 2799067 T3 DK2799067 T3 DK 2799067T3 DK 14175859 T DK14175859 T DK 14175859T DK 2799067 T3 DK2799067 T3 DK 2799067T3
Authority
DK
Denmark
Prior art keywords
treatment
brain inflammation
ornithine phenylacetate
phenylacetate
ornithine
Prior art date
Application number
DK14175859.9T
Other languages
English (en)
Inventor
Rajiv Jalan
Keith Anderson
Original Assignee
Ucl Business Plc
Ocera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucl Business Plc, Ocera Therapeutics Inc filed Critical Ucl Business Plc
Application granted granted Critical
Publication of DK2799067T3 publication Critical patent/DK2799067T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DK14175859.9T 2009-06-08 2010-06-08 Behandling af hjerneinflammation ved anvendelse af L-Ornithin-phenylacetat DK2799067T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18515809P 2009-06-08 2009-06-08
US24074809P 2009-09-09 2009-09-09
US29637710P 2010-01-19 2010-01-19
EP10786721.0A EP2440200B8 (en) 2009-06-08 2010-06-08 Treatment of portal hypertension using l-ornithine phenylacetate

Publications (1)

Publication Number Publication Date
DK2799067T3 true DK2799067T3 (da) 2019-06-03

Family

ID=43309444

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10786721.0T DK2440200T3 (da) 2009-06-08 2010-06-08 Behandling af portal hypertension ved anvendelse af l-ornithinphenylacetat
DK14175859.9T DK2799067T3 (da) 2009-06-08 2010-06-08 Behandling af hjerneinflammation ved anvendelse af L-Ornithin-phenylacetat

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK10786721.0T DK2440200T3 (da) 2009-06-08 2010-06-08 Behandling af portal hypertension ved anvendelse af l-ornithinphenylacetat

Country Status (19)

Country Link
US (2) US20120157526A1 (da)
EP (3) EP2799067B1 (da)
JP (3) JP5749255B2 (da)
KR (2) KR20170026672A (da)
CN (2) CN104434894A (da)
AU (1) AU2010258888B2 (da)
BR (1) BRPI1012956A8 (da)
CA (2) CA2764587C (da)
DK (2) DK2440200T3 (da)
EA (2) EA201691430A1 (da)
ES (2) ES2728948T3 (da)
HK (2) HK1174264A1 (da)
IL (2) IL216811A (da)
MX (2) MX2011013129A (da)
NZ (2) NZ596916A (da)
PL (1) PL2440200T3 (da)
SG (1) SG176675A1 (da)
WO (1) WO2010144498A2 (da)
ZA (1) ZA201108988B (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2153870E (pt) 2004-11-26 2014-03-12 Ucl Business Plc Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática
HUE035921T2 (en) 2009-04-03 2018-05-28 Ocera Therapeutics Inc L-Ornithine Phenylacetate and Methods of Preparation
US20120157526A1 (en) 2009-06-08 2012-06-21 Ucl Business Plc Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate
JP6087284B2 (ja) 2010-10-06 2017-03-01 オセラ セラピューティクス， インコーポレイテッド Ｌ−オルニチンフェニルアセテートを製造するための方法
CN102993037B (zh) * 2012-11-20 2015-03-04 南京工业大学 一种l-鸟氨酸苯乙酸盐的制备方法
PT3099306T (pt) 2014-01-29 2019-03-21 Umecrine Cognition Ab Composto esteroide para utilização no tratamento de encefalopatia hepática
PL3978074T3 (pl) 2014-10-24 2024-08-12 Mallinckrodt Pharmaceuticals Ireland Limited Terlipresyna do leczenia zespołu wątrobowo-nerkowego typu 1
KR102487376B1 (ko) * 2014-11-24 2023-01-10 유씨엘 비즈니스 리미티드 암모니아-저감 치료를 이용한 간성상세포 활성화와 연관된 질병의 치료
AR103384A1 (es) 2015-01-12 2017-05-03 Umecrine Cognition Ab 3a-ETINILO, 3b-HIDROXI, 5a-PREGNAN-20-OXIMA COMO MODULADOR DE GABA
DK3285756T3 (da) * 2015-04-20 2023-05-08 Ocera Therapeutics Inc Formuleringer af l-ornithinphenylacetat
JP2017014206A (ja) * 2015-06-30 2017-01-19 ナノアンティバイオティクス，インコーポレイテッド 腹水の治療
EP3337473A4 (en) * 2015-08-18 2019-04-17 Ocera Therapeutics, Inc. TREATMENT AND PREVENTION OF MUSCLE WOUND BY L-ORNITHIN IN COMBINATION WITH AT LEAST ONE PHENYL ACETATE AND PHENYL BUTYRATE
WO2017053613A1 (en) * 2015-09-25 2017-03-30 Ocera Therapeutics, Inc. Treatment and prevention of neuronal cell loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate
US11219611B2 (en) * 2015-11-13 2022-01-11 Ocera Therapeutics, Inc. Formulations of L-ornithine phenylacetate
AU2016353350B2 (en) * 2015-11-13 2021-09-23 Ocera Therapeutics, Inc. Formulation of L-ornithine phenylacetate
CN106109429A (zh) * 2016-07-26 2016-11-16 北京百奥药业有限责任公司 一种苯丁酸钠片剂及其制备方法
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
US11160826B1 (en) 2017-03-03 2021-11-02 United States Government As Represented By The Department Of Veterans Affairs Cholesterol lowering drugs for the treatment of hepatic encephalopathy
US11066352B2 (en) 2017-05-11 2021-07-20 Ocera Therapeutics, Inc. Processes of making L-ornithine phenylacetate
AU2018318112A1 (en) 2017-08-14 2020-02-13 Axcella Health Inc. Amino acid for the treatment of liver disease
WO2019173148A1 (en) * 2018-03-05 2019-09-12 The United States Government As Represented By The United States Department Of Veterans Affairs Cholesterol lowering drugs for the treatment of hepatic encephalopathy
US10596136B2 (en) 2018-06-20 2020-03-24 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
KR102237526B1 (ko) * 2019-11-07 2021-04-07 한국식품연구원 오르니틴 생성능이 우수한 락토바실러스 브레비스 wikim47를 이용한 마늘 발효 조성물

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB965637A (en) 1962-04-23 1964-08-06 Tanabe Seiyaku Co L-ornithine l-aspartate
NL302572A (da) 1962-12-27
GB1067742A (en) 1963-09-16 1967-05-03 Kyowa Hakko Kogyo Kk Process for the preparation of l-ornithine l-aspartate
ZA716628B (en) 1970-10-15 1972-06-28 Richardson Merrell Spa Composition and method for treatment of hepatic disease and mental fatigue
FR2113774A1 (en) 1970-11-13 1972-06-30 Roques Ets Prepn of l-ornithine salts with org acids - using silver oxides
US4100161A (en) 1974-04-15 1978-07-11 The Johns Hopkins University Promotion of protein synthesis and suppression of urea formation in the body by keto analogs of essential amino acids
US3950529A (en) 1975-02-03 1976-04-13 Massachusetts General Hospital Amino acid formulations for patients with liver disease and method of using same
US4228099A (en) 1978-03-17 1980-10-14 The Johns Hopkins University Ornithine and arginine salts of branched chain keto acids and uses in treatment of hepatic and renal disorders
US4320146A (en) 1978-03-17 1982-03-16 The Johns Hopkins University Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids
US4352814A (en) 1979-04-18 1982-10-05 The Johns Hopkins University Treatment of hepatic and renal disorders with mixed salts of essential or semi-essential amino acids and nitrogen-free analogs
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4457942A (en) 1982-08-20 1984-07-03 Brusilow Saul W Process for waste nitrogen removal
US4857555A (en) 1985-09-12 1989-08-15 Brigham & Women's Hospital Method of treating catabolic dysfunction
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
US5139981A (en) 1987-06-24 1992-08-18 Union Carbide Chemicals & Plastics Technology Corporation Process for preparing silver(I)-exchanged resins
JP2522034B2 (ja) 1988-12-27 1996-08-07 味の素株式会社 α−ケト酸・アミノ酸塩化合物及びその製造方法
US5591613A (en) 1990-07-02 1997-01-07 Degussa Aktiengesellschaft Method for the preparation of D-arginine and L-ornithine
DE4020980C1 (da) 1990-07-02 1991-09-26 Degussa Ag, 6000 Frankfurt, De
JP3127484B2 (ja) 1991-02-28 2001-01-22 味の素株式会社 肝炎治療薬
US5767086A (en) 1992-04-03 1998-06-16 Terrapin Technologies, Inc. Bone marrow stimulation by certain glutathione analogs
US5571783A (en) 1993-03-09 1996-11-05 Clintec Nutrition Company Composition and method for treating patients with hepatic disease
JP3273578B2 (ja) 1993-09-21 2002-04-08 第一化学薬品株式会社 オルニチンと酸性アミノ酸類又はケト酸類との塩の製造法
US6083953A (en) 1994-07-28 2000-07-04 Syntex (U.S.A.) Inc. 2- (2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3- propanediol derivative
IL116674A (en) 1995-01-09 2003-05-29 Mendell Co Inc Edward Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof
KR19980702436A (ko) * 1995-02-23 1998-07-15 하인쯔 쉬나이더, 미첼 오르진거 아미노산 조성물 및 임상용 영양물내에 이의 사용 방법
WO1997030167A1 (en) 1996-02-13 1997-08-21 The Trustees Of The University Of Pennsylvania Method of treating liver disorders
ZA986614B (en) 1997-07-25 1999-01-27 Gilead Sciences Nucleotide analog composition
GB9815567D0 (en) 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
US6258849B1 (en) 1998-07-23 2001-07-10 Stanislaw R. Burzynski Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
CA2374273A1 (en) 1999-05-21 2000-11-30 Takeda Chemical Industries, Ltd. Liver function controlling agents
US6768024B1 (en) 2000-08-04 2004-07-27 Lion Bioscience Ag Triamine derivative melanocortin receptor ligands and methods of using same
JP3211824B1 (ja) 2000-10-26 2001-09-25 味の素株式会社 分岐鎖アミノ酸含有医薬用顆粒製剤とその製造方法
CN1304723A (zh) 2001-01-16 2001-07-25 中山大学 含二氢呋喃环结构的丹参酮类化合物用于治疗肝性脑病的药物
ATE441409T1 (de) 2001-03-15 2009-09-15 Riken Aminosäurezusammensetzungen zur linderung einer fehlfunktion der leber
US6503530B1 (en) 2001-11-01 2003-01-07 Chunghee Kimberly Kang Method of preventing development of severe metabolic derangement in inborn errors of metabolism
US20030105104A1 (en) 2001-11-27 2003-06-05 Burzynski Stanislaw R. Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy
US20030195255A1 (en) 2002-04-12 2003-10-16 Summar Marshall L. Method for treating hepatic encephalopathies
US20040229948A1 (en) 2002-04-12 2004-11-18 Summar Marshall L. Method for preventing hepatic encephalopathic episodes
CN1383815A (zh) 2002-05-08 2002-12-11 刘万忠 防治肝病、肝性脑病的鸟氨酸和门冬氨酸的复方制剂及其制备方法
US20040152784A1 (en) 2002-07-23 2004-08-05 Special Products Limited Pharmaceutical composition and method for treatment of a urea cycle deficiency or sickle-cell anaemia
JPWO2004019928A1 (ja) 2002-08-30 2005-12-15 味の素株式会社 肝疾患治療剤
US20050059150A1 (en) 2003-09-17 2005-03-17 Becton, Dickinson And Company Environments that maintain function of primary liver cells
MXPA03009902A (es) 2003-10-29 2005-05-03 Manuel Francisco Lara Och Jose Compuestos para reducir la hiperamonemia en pacientes con cirrosis u otras incapacidad para la eliminacion de amonio.
JP5064037B2 (ja) 2004-02-23 2012-10-31 ジェネンテック， インコーポレイテッド 複素環式自壊的リンカーおよび結合体
AU2005240257B2 (en) 2004-05-06 2011-11-24 Osteologix A/S High yield and rapid syntheses methods for producing metallo-organic salts
US20060045912A1 (en) 2004-08-30 2006-03-02 Peter Truog 4-phenylbutyric acid controlled-release formulations for therapeutic use
PT2153870E (pt) * 2004-11-26 2014-03-12 Ucl Business Plc Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática
GB0426141D0 (en) * 2004-11-26 2004-12-29 Ucl Biomedica Plc Treatment
WO2007077995A1 (ja) 2006-01-05 2007-07-12 Kyowa Hakko Kogyo Co., Ltd. 筋肉増量剤
DE102007009243A1 (de) 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets
US20090306209A1 (en) 2008-06-04 2009-12-10 Daugherty F Joseph Enteric-coated formulations of polyethylene glycol and one or more soluble amino acids for oral ingestion and enhanced uptake of same
HUE035921T2 (en) 2009-04-03 2018-05-28 Ocera Therapeutics Inc L-Ornithine Phenylacetate and Methods of Preparation
AU2015221466B2 (en) 2009-04-03 2017-02-02 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
CA2763894A1 (en) 2009-06-02 2011-01-13 Salix Pharmaceuticals, Ltd. Use of rifaximin to maintain remission of hepatic encephalopathy
AU2014250643B2 (en) 2009-06-08 2016-07-14 Ocera Therapeutics, Inc. Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate
US20120157526A1 (en) 2009-06-08 2012-06-21 Ucl Business Plc Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate
JP2011236160A (ja) 2010-05-11 2011-11-24 Shinshu Univ 非アルコール性肝疾患治療薬
JP6087284B2 (ja) 2010-10-06 2017-03-01 オセラ セラピューティクス， インコーポレイテッド Ｌ−オルニチンフェニルアセテートを製造するための方法
AU2013347905B2 (en) 2012-11-21 2018-10-04 Immedica Pharma Ab Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy
CN103705490B (zh) 2013-10-31 2016-08-17 蚌埠丰原医药科技发展有限公司 一种门冬氨酸鸟氨酸的缓释制剂及其制备工艺
KR102487376B1 (ko) 2014-11-24 2023-01-10 유씨엘 비즈니스 리미티드 암모니아-저감 치료를 이용한 간성상세포 활성화와 연관된 질병의 치료
DK3285756T3 (da) 2015-04-20 2023-05-08 Ocera Therapeutics Inc Formuleringer af l-ornithinphenylacetat
EP3337473A4 (en) 2015-08-18 2019-04-17 Ocera Therapeutics, Inc. TREATMENT AND PREVENTION OF MUSCLE WOUND BY L-ORNITHIN IN COMBINATION WITH AT LEAST ONE PHENYL ACETATE AND PHENYL BUTYRATE
WO2017053613A1 (en) 2015-09-25 2017-03-30 Ocera Therapeutics, Inc. Treatment and prevention of neuronal cell loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate
US11219611B2 (en) 2015-11-13 2022-01-11 Ocera Therapeutics, Inc. Formulations of L-ornithine phenylacetate

Also Published As

Publication number Publication date
EP2799067A1 (en) 2014-11-05
EP3517110A1 (en) 2019-07-31
BRPI1012956A2 (pt) 2017-06-06
WO2010144498A9 (en) 2011-04-28
EP2440200A4 (en) 2012-11-28
US11266620B2 (en) 2022-03-08
HK1174264A1 (en) 2013-06-07
JP5749255B2 (ja) 2015-07-15
NZ596916A (en) 2013-09-27
DK2440200T3 (da) 2014-12-08
CA2764587C (en) 2018-04-24
IL248696B (en) 2020-05-31
ES2517340T3 (es) 2014-11-03
EA201171396A1 (ru) 2012-10-30
US20180161293A1 (en) 2018-06-14
AU2010258888A1 (en) 2012-02-02
EA025735B1 (ru) 2017-01-30
MX2020009703A (es) 2020-10-07
CA2997484C (en) 2020-05-12
JP2015163635A (ja) 2015-09-10
KR20170026672A (ko) 2017-03-08
ES2728948T3 (es) 2019-10-29
JP2017066153A (ja) 2017-04-06
IL216811A (en) 2016-11-30
CA2764587A1 (en) 2010-12-16
US20120157526A1 (en) 2012-06-21
KR101715008B1 (ko) 2017-03-22
EP2440200B8 (en) 2014-10-15
CN104434894A (zh) 2015-03-25
CN102625699B (zh) 2014-08-20
EP2440200B1 (en) 2014-08-27
IL248696A0 (en) 2016-12-29
CN102625699A (zh) 2012-08-01
WO2010144498A2 (en) 2010-12-16
EP2440200A2 (en) 2012-04-18
BRPI1012956A8 (pt) 2021-11-03
CA2997484A1 (en) 2010-12-16
KR20120047891A (ko) 2012-05-14
JP2012529523A (ja) 2012-11-22
JP6250588B2 (ja) 2017-12-20
ZA201108988B (en) 2015-04-29
SG176675A1 (en) 2012-01-30
NZ615091A (en) 2015-03-27
EA201691430A1 (ru) 2017-02-28
JP6527497B2 (ja) 2019-06-05
MX2011013129A (es) 2012-03-14
EP2799067B1 (en) 2019-04-03
HK1203419A1 (en) 2015-10-30
IL216811A0 (en) 2012-02-29
AU2010258888B2 (en) 2014-08-07
PL2440200T3 (pl) 2015-08-31

Similar Documents

Publication Publication Date Title
DK2799067T3 (da) Behandling af hjerneinflammation ved anvendelse af L-Ornithin-phenylacetat
SMT201600129B (it) Trattamento della lipodistrofia
DK2635299T3 (da) Fremgangsmåder til behandling af hårtabsforstyrrelser
DK2575762T3 (da) Fjernelse af serinproteaser ved behandling med findelt silicium-dioxid
BRPI0910259A2 (pt) métodos de tratamento de inflamação
DK2785349T3 (da) Kombinationsbehandling af cancer
DK2717941T3 (da) Behandling af cancer
DK2701733T3 (da) Forbindelser til behandling af neuropsykiatriske forstyrrelser
CO6811859A2 (es) Método de tratamiento de los trastornos de la visión
HK1199015A1 (en) Treatment of inflammation
BR112014015551A8 (pt) método para tratar lama e método para desidratação de lama
DK2252317T3 (da) Behandling af makuladegeneration
BR112013007537A2 (pt) "processo de tratamento de biomassa"
DK2326332T3 (da) Fremgangsmåde til behandling af sygdomme
EP2480579A4 (en) METHODS OF TREATING INFLAMMATION
DK2501381T3 (da) Behandling af atrieflimmer
DK2435583T3 (da) miR-31 VED BEHANDLING AF DUCHENNES MUSKELDYSTROFI
BR112012029016A2 (pt) processo de redução direta
BRPI1007543A2 (pt) tratamento de psoríase
EP2473171A4 (en) METHODS OF TREATING MITOCHONDRIAL DISORDERS USING METALLOPORPHYRINS
DK2673363T3 (da) Behandling af angiogenesesygdomme
IT1392635B1 (it) Trattamento ematico di ozonoterapia
FI20106078A0 (fi) Puukuitupitoisen jakeen käsittely
BR112014008845A2 (pt) processo de tratamento anticorrosão
DK2780003T3 (da) Behandling af binyrebarkinsufficiens